Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:CDAK

Codiak BioSciences (CDAK) Stock Price, News & Analysis

Codiak BioSciences logo

About Codiak BioSciences Stock (NASDAQ:CDAK)

Advanced Chart

Key Stats

Today's Range
$0.0016
$0.0016
50-Day Range
N/A
52-Week Range
$0.05
$6.98
Volume
N/A
Average Volume
1.37 million shs
Market Capitalization
$58,928.00
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Codiak BioSciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing exosome-based therapeutics for the treatment of oncology, neuro-oncology, neurology, neuromuscular diseases, infectious diseases, and other diseases. Its lead product candidates are exoSTING and exoIL-12 exosome therapeutic candidates for the treatment of various solid tumors. The company is also developing exoASO-STAT6, an antisense oligonucleotide targeting the STAT6 transcription factor; and exoVACC, a modular platform for constructing precision vaccines. It has a collaboration agreement with the Jazz Pharmaceuticals Ireland Limited, Sarepta Therapeutics, Inc., Kayla Therapeutics S.A.S., Washington University, Ragon Institute of MGH, MIT, and Harvard. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Receive CDAK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Codiak BioSciences and its competitors with MarketBeat's FREE daily newsletter.

CDAK Stock News Headlines

Marvel Biosciences Corp MRVL
Is President Trump Lying To You With This?
President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to protect your 401(k), IRA, or pension from market chaos and currency collapse? The 2025 Wealth Protection Guide reveals a legal IRS strategy that may let you keep more of your retirement—regardless of what happens next. Trump’s warning was real. So is this opportunity.
CDAK.O
Codiak BioSciences Files For Chapter 11 Bankruptcy
See More Headlines

CDAK Stock Analysis - Frequently Asked Questions

Codiak BioSciences, Inc. (NASDAQ:CDAK) released its quarterly earnings results on Thursday, November, 4th. The company reported ($0.97) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.85) by $0.12. The company earned $1.16 million during the quarter, compared to analyst estimates of $2.87 million. Codiak BioSciences had a negative net margin of 51.13% and a negative trailing twelve-month return on equity of 109.51%.

Codiak BioSciences (CDAK) raised $82 million in an initial public offering on Wednesday, October 14th 2020. The company issued 5,500,000 shares at a price of $14.00-$16.00 per share. Goldman Sachs, Evercore ISI, William Blair and Wedbush PacGrow acted as the underwriters for the IPO.

Based on aggregate information from My MarketBeat watchlists, some other companies that Codiak BioSciences investors own include NIO (NIO), Advanced Micro Devices (AMD), Alibaba Group (BABA), NVIDIA (NVDA), PayPal (PYPL), Tesla (TSLA) and Plug Power (PLUG).

Company Calendar

Last Earnings
11/04/2021
Today
5/28/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:CDAK
Fax
N/A
Employees
102
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$37.16 million
Pretax Margin
-51.13%

Debt

Sales & Book Value

Annual Sales
$33.57 million
Price / Cash Flow
N/A
Book Value
$2.39 per share
Price / Book
0.00

Miscellaneous

Free Float
33,810,000
Market Cap
$58,928.00
Optionable
Not Optionable
Beta
3.71
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for June 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

This page (NASDAQ:CDAK) was last updated on 5/29/2025 by MarketBeat.com Staff
From Our Partners